Active, not recruitingPhase 2NCT06239532

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Qilu Hospital of Shandong University
Principal Investigator
Zongli Zhang
Qilu Hospital of Shandong University
Intervention
HAIC+TAE(drug)
Enrollment
28 target
Eligibility
18-80 years · All sexes
Timeline
20222025

Study locations (1)

Collaborators

BeiGene

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06239532 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials